文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

草药提取物恢复COVID-19轻中症患者呼吸健康及增强先天免疫的安全性和有效性:随机对照试验方案结构化摘要

Safety and efficacy of herbal extracts to restore respiratory health and improve innate immunity in COVID-19 positive patients with mild to moderate severity: A structured summary of a study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2020-11-23

该试验为单中心、随机、双盲、平行对照探索性研究,纳入72例RT-PCR确诊的COVID-19轻中症患者,按1:1分配至草药提取物组(37例)或安慰剂组(35例)。主要结局为第4天病毒载量下降及早期康复,次要结局包括免疫调节指标及安全性。

要点

  • 草药提取物组与安慰剂组按1:1随机,双盲设计。
  • 主要结局关注第4天病毒载量下降和早期康复。
  • 安全性评估包括肝肾功能及严重过敏反应。

核心结论

  • 该方案旨在评估草药提取物增强COVID-19患者先天免疫及恢复呼吸健康的有效性和安全性,结果尚未报告。

研究设计与样本

  • 单中心、随机、2臂、平行组、双盲、1:1比例、对照、探索性试验,研究周期30天。
  • 计划入组超过60例至75例,实际入组72例,干预组37例,安慰剂组35例。
  • 纳入标准为RT-PCR确诊的COVID-19阳性且符合条件并愿意参加的患者。

关键数值与推荐

  • 干预组每日两次口服两粒胶囊(IP-1 400mg和IP-2 450mg),共15天;第16天起每日两次口服一粒IP-2 450mg至第30天。
  • 主要结局为第4天病毒载量下降及早期康复。
  • 次要结局包括TH1、TH2、Th17、IL6、NK细胞、CD标志物、血清IgG和IgM(第30天)、后遗症减少及安全性(肝功能、肾功能、严重过敏反应)。
  • 安慰剂为食用淀粉约450mg,外观与IP相似。

局限性

  • 单中心、探索性设计,样本量有限(72例)。
  • 方案发表为入组结束后迟交。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Primary Objective • To assess the efficacy of herbal extracts in boosting innate immunity of patients with COVID-19 infection. Secondary Objectives • To assess the efficacy of herbal extracts in restoring respiratory health • To assess the efficacy of Cap. IP in early recovery of patients and decline in viral load • To assess the safety of herbal extracts TRIAL DESIGN: This is a single centre, randomized, 2-arm, parallel group, double blind, 1:1 ratio, controlled, exploratory trial with a study period of 30 days from the day of enrolment. PARTICIPANTS: Patients attending the COVID treatment centre at Yashwantrao Chavan Memorial Hospital, Nehrunagar, Pimpri, Pune, India were screened for their participation in the study. Patients who were known COVID-19 positive (with positive RT-PCR), eligible and willing were enrolled in the study. INTERVENTION AND COMPARATOR: The intervention in the trial has a background in 'Ayurved'. Intervention Arm: Two capsules, Investigational Product (IP) - 1 - 400mg and Investigational Product - 2 - 450mg, containing herbal extracts (a blend of water and CO2 extracts) of Shunthi (Zingiber officinale (Ginger), Vidanga (Embelia ribes), Yashtimadhu (Glycyrrhiza glabra), Haritaki (Terminalia chebula), Guduchi (Tinospora cordifolia), Shatavari (Asparagus racemosus), Aamalaki (Emblica officinalis), Pippali (Piper longum) and calcined Zinc, Shankha bhasma. Placebo Arm: Edible starch ~ 450 mg. The look and feel of IP and of Placebo boxes were very similar. Patients are to take two capsules (one each of IP-1 and IP-2) twice a day for 15 days, and from the 16th day, one capsule of IP-2 twice a day up-to day 30. Capsules are to be administered orally with plain water. The IP is to be taken with all other concomitant medicines prescribed by the treating physician/doctor. The dose of each component in the IP is very safe to administer. The investigational products are registered products with the Indian Government and have been used for more than 6 months in various health conditions but not for COVID-19. MAIN OUTCOMES: Primary Outcome: Efficacy of the herbal extracts in COVID 19 positive patients (in declining viral load: time-point: 4 days and early recovery) Secondary Outcomes: Efficacy of the herbal extracts as an immune-modulator - TH1, TH2, Th17, IL6, NK Cells and CD markers; Immunoglobulin IGG (Serum); Immunoglobulin IGM (Serum) - at 30 days. Efficacy of the investigational product in reducing sequela of the disease Safety analysis (Liver Function Test and Kidney Function Test) including serious allergic reaction of: rash, itching/swelling, severe dizziness, trouble breathing. RANDOMISATION: An alphanumeric coded set of IP/Placebo containers will be used. Participants will be automatically randomized to two groups in the ratio 1:1. BLINDING (MASKING): Participants, caregivers and investigators were blinded. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): A total of more than 60 and up to 75 patients were to be enrolled in the study into the two groups, considering drop-outs. 72 were enrolled with 37 into the intervention group and 35 into the placebo group. TRIAL STATUS: Protocol number: CoviQuest-01 Protocol version number: 1.2 Protocol Date: 1st July 2020 The recruitment period is completed for the trial. Date of 1st patient enrolment was 11th Aug 2020 and the last patient was enrolled on 3rd of September 2020. This is to state that it was a late submission from authors for publication of the protocol to the BMC, after enrolment in the study was over. Last Participant's last follow-up is scheduled on 5th October 2020 TRIAL REGISTRATION: The trial was prospectively registered with the CTRI (Clinical Trial Registry of India). Registration number is CTRI/2020/07/026570 . Registered on 14 July 2020 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Rangnekar H, Patankar S, Suryawanshi K, et al. Safety and efficacy of herbal extracts to restore respiratory health and improve innate immunity in COVID-19 positive patients with mild to moderate severity: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020. PMID: 33225970. doi:10.1186/s13063-020-04906-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。